{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:36:18Z","timestamp":1791948978965,"version":"4.3.4"},"reference-count":63,"publisher":"Oncology Nursing Society (ONS)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ONF"],"published-print":{"date-parts":[[2020,9,1]]},"DOI":"10.1188\/20.onf.539-556","type":"journal-article","created":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T08:19:01Z","timestamp":1598257141000},"page":"539-556","source":"Crossref","is-referenced-by-count":27,"title":["ONS Guidelines\u2122 for Cancer Treatment\u2013Related Skin Toxicity"],"prefix":"10.1188","volume":"47","author":[{"given":"Loretta","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Ginex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Ebanks Jr.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karren","family":"Ganstwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Ciccolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernice","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanene","family":"Robison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Strelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Wiley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri","family":"Moriarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Vrabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1302","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Abdel-Rahman, O., & Fouad, M. (2015). Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: A systematic review and meta-analysis. Critical Reviews in Oncology\/Hematology, 93(2), 127\u2013135. https:\/\/doi.org\/10.1016\/j.critrevonc.2014.07.005","DOI":"10.1016\/j.critrevonc.2014.07.005"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Arrieta, O., Vega-Gonz\u00e1lez, M.T., L\u00f3pez-Mac\u00edas, D., Mart\u00ednez-Hern\u00e1ndez, J.N., Bacon-Fonseca, L., Macedo-P\u00e9rez, E.O., . . . de la Garza-Salazar, J. (2015). Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients. Lung Cancer, 88(3), 282\u2013288. https:\/\/doi.org\/10.1016\/j.lungcan.2015.03.019","DOI":"10.1016\/j.lungcan.2015.03.019"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Balagula, Y., Rosen, S.T., & Lacouture, M.E. (2011). The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies. Journal of the American Academy of Dermatology, 65(3), 624\u2013635.","DOI":"10.1016\/j.jaad.2010.06.051"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Balshem, H., Helfand, M., Sch\u00fcnemann, H.J., Oxman, A.D., Kunz, R., Brozek, J., . . . Norris, S. (2011). GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology, 64(4), 401\u2013406. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.07.015","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Betticher, D.C., Delmore, G., Breitenstein, U., Anchisi, S., Zimmerli-Schwab, B., M\u00fcller, A., . . . Trueb, R.R. (2013). Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment. Supportive Care in Cancer, 21(9), 2565\u20132573.","DOI":"10.1007\/s00520-013-1804-9"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Boyle, F.M., Shaw, J., Young, A., van den Hurk, C., Rugo, H.S., Fogarty, G.B., & Lacouture, M.E. (2018). Management of alopecia due to cancer therapies. In I. Olver (ed.), The MASCC textbook of cancer supportive care and survivorship (2nd ed., pp. 621\u2013631). Springer. https:\/\/doi.org\/10.1007\/978-3-319-90990-5_38","DOI":"10.1007\/978-3-319-90990-5_38"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Braden, R.L., & Anadkat, M.J. (2016). EGFR inhibitor-induced skin reactions: Differentiating acneiform rash from superimposed bacterial infections. Supportive Care in Cancer, 24(9), 3943\u20133950. https:\/\/doi.org\/10.1007\/s00520-016-3231-1","DOI":"10.1007\/s00520-016-3231-1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Braik, T., Yim, B., Evans, A., Kassem, M., Mullane, M., Lad, T., . . . McDunn, S. (2014). Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy. Journal of Community and Supportive Oncology, 12(2), 65\u201370. https:\/\/doi.org\/10.12788\/jcso.0017","DOI":"10.12788\/jcso.0017"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Chu, D., Lacouture, M.E., Fillos, T., & Wu, S. (2008). Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis. Acta Oncologica, 47(2), 176\u2013186. https:\/\/doi.org\/10.1080\/02841860701765675","DOI":"10.1080\/02841860701765675"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Corrie, P.G., Bulusu, R., Wilson, C.B., Armstrong, G., Bond, S., Hardy, R., . . . Osborne, M. (2012). A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. British Journal of Cancer, 107(4), 585\u2013587. https:\/\/doi.org\/10.1038\/bjc.2012.318","DOI":"10.1038\/bjc.2012.318"},{"key":"11","doi-asserted-by":"crossref","unstructured":"De Wit, M., Boers-Doets, C.B., Saettini, A., Vermeersch, K., de Juan, C.R., Ouwerkerk, J., . . . Cremolini, C. (2014). Prevention and management of adverse events related to regorafenib. Supportive Care in Cancer, 22(3), 837\u2013846. https:\/\/doi.org\/10.1007\/s00520-013-2085-z","DOI":"10.1007\/s00520-013-2085-z"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Degen, A., Alter, M., Schenck, F., Satzger, I., V\u00f6lker, B., Kapp, A., & Gutzmer, R. (2010). The hand-foot-syndrome associated with medical tumor therapy\u2014Classification and management. JDDG: Journal of the German Society of Dermatology, 8(9), 652\u2013661. https:\/\/doi.org\/10.1111\/j.1610-0387.2010.07449.x","DOI":"10.1111\/j.1610-0387.2010.07449.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Ding, J.F., Farah, M.H., Nayfeh, T., Malandris, K., Manolopoulos, A., Ginex, P.K., . . . Murad, M.H. (2020). Targeted therapy\u2013 and chemotherapy-associated skin toxicities: Systematic review and meta-analysis. Oncology Nursing Forum, 47(5), E149\u2013E160. https:\/\/doi.org\/10.1188\/20.ONF.E149-E160","DOI":"10.1188\/20.ONF.E149-E160"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Duvic, M., Lemak, N.A., Valero, V., Hymes, S.R., Farmer, K.L., Hortobagyi, G.N., . . . Compton, L.D. (1996). A randomized trial of minoxidil in chemotherapy-induced alopecia. Journal of the American Academy of Dermatology, 35(1), 74\u201378. https:\/\/doi.org\/10.1016\/S0190-9622(96)90500-9","DOI":"10.1016\/S0190-9622(96)90500-9"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Freites-Martinez, A., Chan, D., Sibaud, V., Shapiro, J., Fabbrocini, G., Tosti, A., . . . Lacouture, M.E. (2019). Assessment of quality of life and treatment outcomes of patients with persistent postchemotherapy alopecia. JAMA Dermatology, 155(6), 724\u2013728. https:\/\/doi.org\/10.1001\/jamadermatol.2018.5071","DOI":"10.1001\/jamadermatol.2018.5071"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Gabra, H., Cameron, D.A., Lee, L.E., Mackay, J., & Leonard, R.C.F. (1996). Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. British Journal of Cancer, 74(12), 2008\u20132012. https:\/\/doi.org\/10.1038\/bjc.1996.668","DOI":"10.1038\/bjc.1996.668"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Graham, R., Mancher, M., Miller Wolman, D., Greenfield, S., & Steinberg, E. (Eds.). (2011). Clinical practice guidelines we can trust. National Academies Press. https:\/\/doi.org\/10.17226\/13058","DOI":"10.17226\/13058"},{"key":"18","unstructured":"Granai, C.O., Frederickson, H., Gajewski, W., Goodman, A., Goldstein, A., & Baden, H. (1991). The use of minoxidil to attempt to prevent alopecia during chemotherapy for gynecologic malignancies. European Journal of Gynaecological Oncology, 12(2), 129\u2013132."},{"key":"19","doi-asserted-by":"crossref","unstructured":"Guyatt, G., Oxman, A.D., Akl, E.A., Kunz, R., Vist, G., Brozek, J., . . . deBeer, H. (2011). GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology, 64(4), 383\u2013394. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.04.026","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Guyatt, G.H., Oxman, A.D., Kunz, R., Atkins, D., Brozek, J., Vist, G., . . . Sch\u00fcnemann, H.J. (2011). GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology, 64(4), 395\u2013400. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.09.012","DOI":"10.1016\/j.jclinepi.2010.09.012"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Guyatt, G.H., Oxman, A.D., Sultan, S., Glasziou, P., Akl, E.A., Alonso-Coello, P., . . . Sch\u00fcnemann, H.J. (2011). GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology, 64(12), 1311\u20131316. https:\/\/doi.org\/10.1016\/j.jclinepi.2011.06.004","DOI":"10.1016\/j.jclinepi.2011.06.004"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Jatoi, A., Dakhil, S.R., Sloan, J.A., Kugler, J.W., Rowland, K.M., Schaefer, P.L., . . . Loprinzi, C.L. (2011). Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: Results from the North Central Cancer Treatment Group (Supplementary N03CB). Supportive Care in Cancer, 19(10), 1601\u20131607. https:\/\/doi.org\/10.1007\/s00520-010-0988-5","DOI":"10.1007\/s00520-010-0988-5"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Jatoi, A., Rowland, K., Sloan, J.A., Gross, H.M., Fishkin, P.A., Kahanic, S.P., . . . Loprinzi, C.L. (2008). Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer, 113(4), 847\u2013853. https:\/\/doi.org\/10.1002\/cncr.23621","DOI":"10.1002\/cncr.23621"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Joshi, S.S., Ortiz, S., Witherspoon, J.N., Rademaker, A., West, D.P., Anderson, R., . . . Lacouture, M.E. (2010). Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer, 116(16), 3916\u20133923. https:\/\/doi.org\/10.1002\/cncr.25090","DOI":"10.1002\/cncr.25090"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Kang, Y.K., Lee, S.S., Yoon, D.H., Lee, S.Y., Chun, Y.J., Kim, M.S., . . . Kim, T.W. (2010). Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: Results of a randomized, double-blind, placebo-controlled study. Journal of Clinical Oncology, 28(24), 3824\u20133829. https:\/\/doi.org\/10.1200\/jco.2010.29.1807","DOI":"10.1200\/JCO.2010.29.1807"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Kargar, M., Sarvestani, R.S., Khojasteh, H.N., & Heidari, M.T. (2011). Efficacy of penguin cap as scalp cooling system for prevention of alopecia in patients undergoing chemotherapy. Journal of Advanced Nursing, 67(11), 2473\u20132477. https:\/\/doi.org\/10.1111\/j.1365-2648.2011.05668.x","DOI":"10.1111\/j.1365-2648.2011.05668.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Lacouture, M.E. (2006). Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature Reviews Cancer, 6(10), 803\u2013812. https:\/\/doi.org\/10.1038\/nrc1970","DOI":"10.1038\/nrc1970"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Lacouture, M.E., Anadkat, M.J., Bensadoun, R.J., Bryce, J., Chan, A., Epstein, J.B., . . . Murphy, B.A. (2011). Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Supportive Care in Cancer, 19(8), 1079\u20131095. https:\/\/doi.org\/10.1007\/s00520-011-1197-6","DOI":"10.1007\/s00520-011-1197-6"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Lacouture, M.E., Mitchell, E.P., Piperdi, B., Pillai, M.V., Shearer, H., Iannotti, N., . . . Yassine, M. (2010). Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 28(8), 1351\u20131357. https:\/\/doi.org\/10.1200\/jco.2008.21.7828","DOI":"10.1200\/JCO.2008.21.7828"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Lacouture, M.E., Wu, S., Robert, C., Atkins, M.B., Kong, H.H., Guitart, J., . . . Dutcher, J.P. (2008). Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist, 13(9), 1001\u20131011. https:\/\/doi.org\/10.1634\/theoncologist.2008-0131","DOI":"10.1634\/theoncologist.2008-0131"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Marks, D.H., Qureshi, A., & Friedman, A. (2018). Evaluation of prevention interventions for taxane-induced dermatologic adverse events: A systematic review. JAMA Dermatology, 154(12), 1465\u20131472. https:\/\/doi.org\/10.1001\/jamadermatol.2018.3465","DOI":"10.1001\/jamadermatol.2018.3465"},{"key":"32","doi-asserted-by":"crossref","unstructured":"McCarthy, A.L., Shaban, R.Z., Gillespie, K., & Vick, J. (2014). Cryotherapy for docetaxel-induced hand and nail toxicity: Randomised control trial. Supportive Care in Cancer, 22(5), 1375\u20131383. https:\/\/doi.org\/10.1007\/s00520-013-2095-x","DOI":"10.1007\/s00520-013-2095-x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"McLellan, B., & Kerr, H. (2011). Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatologic Therapy, 24(4), 396\u2013400. https:\/\/doi.org\/10.1111\/j.1529-8019.2011.01435.x","DOI":"10.1111\/j.1529-8019.2011.01435.x"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Melosky, B., Anderson, H., Burkes, R.L., Chu, Q., Hao, D., Ho, V., Ho . . . Laskin, J.J. (2016). Pan Canadian rash trial: A randomized phase III trial evaluating the impact of a prophylactic skin treatment regimen on epidermal growth factor receptor-tyrosine kinase inhibitor-induced skin toxicities in patients with metastatic lung cancer. Journal of Clinical Oncology, 34(8), 810\u2013815. https:\/\/doi.org\/10.1200\/jco.2015.62.3918","DOI":"10.1200\/JCO.2015.62.3918"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Mols, F., van den Hurk, C.J., Vingerhoets, A.J.J.M., & Breed, W.P.M. (2009). Scalp cooling to prevent chemotherapy-induced hair loss: Practical and clinical considerations. Supportive Care in Cancer, 17(2), 181\u2013189. https:\/\/doi.org\/10.1007\/s00520-008-0475-4","DOI":"10.1007\/s00520-008-0475-4"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Mortimer, J.E., Lauman, M.K., Tan, B., Dempsey, C.L., Shillington, A.C., & Hutchins, K.S. (2003). Pyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabine. Journal of Oncology Pharmacy Practice, 9(4), 161\u2013166. https:\/\/doi.org\/10.1191\/1078155203jp116oa","DOI":"10.1191\/1078155203jp116oa"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Nangia, J., Wang, T., Osborne, C., Niravath, P., Otte, K., Papish, S., . . . Rimawi, M. (2017). Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: The SCALP randomized clinical trial. JAMA, 317(6), 596\u2013605. https:\/\/doi.org\/10.1001\/jama.2016.20939","DOI":"10.1001\/jama.2016.20939"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Nikolaou, V., Syrigos, K., & Saif, M.W. (2016). Incidence and implications of chemotherapy related hand-foot syndrome. Expert Opinion on Drug Safety, 15(12), 1625\u20131633. https:\/\/doi.org\/10.1080\/14740338.2016.1238067","DOI":"10.1080\/14740338.2016.1238067"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Paus, R., Haslam, I.S., Sharov, A.A., & Botchkarev, V.A. (2013). Pathobiology of chemotherapy-induced hair loss. Lancet Oncology, 14(2), e50\u2013e59. https:\/\/doi.org\/10.1016\/S1470-2045(12)70553-3","DOI":"10.1016\/S1470-2045(12)70553-3"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Ren, Z., Zhu, K., Kang, H., Lu, M., Qu, Z., Lu, L., . . . Ye, S. (2015). Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology, 33(8), 894\u2013900. https:\/\/doi.org\/10.1200\/jco.2013.52.9651","DOI":"10.1200\/JCO.2013.52.9651"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Rodriguez, R., Machiavelli, M., Leone, B., Romero, A., Cuevas, M.A., Langhi, M., . . .Lacava, J. (1994). Minoxidil (Mx) as a prophylaxis of doxorubicin-induced alopecia. Annals of Oncology, 5(8), 769\u2013770. https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a058986","DOI":"10.1093\/oxfordjournals.annonc.a058986"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Rossi, A., Fortuna, M.C., Caro, G., Pranteda, G., Garelli, V., Pompili, U., & Carlesimo, M. (2017). Chemotherapy-induced alopecia management: Clinical experience and practical advice. Journal of Cosmetic Dermatology, 16(4), 537\u2013541. https:\/\/doi.org\/10.1111\/jocd.12308","DOI":"10.1111\/jocd.12308"},{"key":"43","doi-asserted-by":"crossref","unstructured":"Rubio-Gonzalez, B., Juh\u00e1sz, M., Fortman, J., & Mesinkovska, N.A. (2018). Pathogenesis and treatment options for chemotherapy-induced alopecia: A systematic review. International Journal of Dermatology, 57(12), 1417\u20131424. https:\/\/doi.org\/10.1111\/ijd.13906","DOI":"10.1111\/ijd.13906"},{"key":"44","doi-asserted-by":"crossref","unstructured":"Rugo, H.S., Melin, S.A., & Voigt, J. (2017). Scalp cooling with adjuvant\/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: Systematic review and meta-analysis. Breast Cancer Research and Treatment, 163(2), 199\u2013205. https:\/\/doi.org\/10.1007\/s10549-017-4185-9","DOI":"10.1007\/s10549-017-4185-9"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Salzmann, M., Marm\u00e9, F., & Hassel, J.C. (2019). Prophylaxis and management of skin toxicities. Breast Care, 14(2), 72\u201377. https:\/\/doi.org\/10.1159\/000497232","DOI":"10.1159\/000497232"},{"key":"46","unstructured":"Scheithauer, W., & Blum, J. (2004). Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Oncology, 18(9), 1161\u20131184."},{"key":"47","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann, H.J., Al-Ansary, L.A., Fortand, F., Kersten, S., Komulainen, J., Kopp, I.B., . . . Qaseem, A. (2015). Guidelines International Network: Principles for disclosure of interests and management of conflicts in guidelines. Annals of Internal Medicine, 163(7), 548\u2013553. https:\/\/doi.org\/10.7326\/M14-1885","DOI":"10.7326\/M14-1885"},{"key":"48","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann, H.J., Wiercioch, W., Etxeandia, I., Flavigna, M., Santesso, N., Mustafa, R., . . . Akl, E.A. (2014). Guidelines 2.0: Systematic development of a comprehensive checklist for a successful guideline enterprise. Canadian Medical Association Journal, 186(3), E123\u2013E142. https:\/\/doi.org\/10.1503\/cmaj.131237","DOI":"10.1503\/cmaj.131237"},{"key":"49","doi-asserted-by":"crossref","unstructured":"Scott\u00e9, F., Banu, E., Medioni, J., Levy, E., Ebenezer, C., Marsan, S., . . . Oudard, S. (2008). Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer, 112(7), 1625\u20131631. https:\/\/doi.org\/10.1002\/cncr.23333","DOI":"10.1002\/cncr.23333"},{"key":"50","doi-asserted-by":"crossref","unstructured":"Scott\u00e9, F., Tourani, J.M., Banu, E., Peyromaure, M., Levy, E., Marsan, S., . . . Oudard, S. (2005). Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. Journal of Clinical Oncology, 23(19), 4424\u20134429. https:\/\/doi.org\/10.1200\/JCO.2005.15.651","DOI":"10.1200\/JCO.2005.15.651"},{"key":"51","doi-asserted-by":"crossref","unstructured":"Shinohara, A., Ikeda, M., Okuyama, H., Kobayashi, M., Funazaki, H., Mitsunaga, S., . . . Saitoh, S. (2015). Efficacy of prophylactic minocycline treatment for skin toxicities induced by erlotinib plus gemcitabine in patients with advanced pancreatic cancer: A retrospective study. American Journal of Clinical Dermatology, 16(3), 221\u2013229. https:\/\/doi.org\/10.1007\/s40257-015-0116-x","DOI":"10.1007\/s40257-015-0116-x"},{"key":"52","doi-asserted-by":"crossref","unstructured":"Tan, E.H., & Chan, A. (2009). Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors. Annals of Pharmacotherapy, 43(10), 1658\u20131666. https:\/\/doi.org\/10.1345\/aph.1M241","DOI":"10.1345\/aph.1M241"},{"key":"53","doi-asserted-by":"crossref","unstructured":"Tr\u00fceb, R.M. (2009). Chemotherapy-induced alopecia. Seminars in Cutaneous Medicine and Surgery, 28(1), 11\u201314. https:\/\/doi.org\/10.1016\/j.sder.2008.12.001","DOI":"10.1016\/j.sder.2008.12.001"},{"key":"54","doi-asserted-by":"crossref","unstructured":"Trusson, D., & Pilnick, A. (2017). The role of hair loss in cancer identity: Perceptions of chemotherapy-induced alopecia among women treated for early-stage breast cancer or ductal carcinoma in situ. Cancer Nursing, 40(2), E9\u2013E16. https:\/\/doi.org\/10.1097\/NCC.0000000000000373","DOI":"10.1097\/NCC.0000000000000373"},{"key":"55","doi-asserted-by":"crossref","unstructured":"Twelves, C., Wong, A., Nowacki, M.P., Abt, M., Burris, H., Carrato, A., . . . Scheithauer, W. (2005). Capecitabine as adjuvant treatment for stage III colon cancer. New England Journal of Medicine, 352(26), 2696\u20132704. https:\/\/doi.org\/10.1056\/NEJMoa043116","DOI":"10.1056\/NEJMoa043116"},{"key":"56","unstructured":"U.K. Oncology Nursing Society. (2020). Acute oncology initial management guidelines [version 2.0]. https:\/\/www.ukons.org\/site\/assets\/files\/1134\/acute_oncology_initial_mana..."},{"key":"57","doi-asserted-by":"crossref","unstructured":"van den Hurk, C.J., Peerbooms, M., van de Poll-Franse, L.V., Nortier, J.W., Coebergh, J.W.W., & Breed, W.P. (2012). Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients\u2014Results of the Dutch Scalp Cooling Registry. Acta Oncologica, 51(4), 497\u2013504. https:\/\/doi.org\/10.3109\/0284186x.2012.658966","DOI":"10.3109\/0284186X.2012.658966"},{"key":"58","doi-asserted-by":"crossref","unstructured":"van den Hurk, C.J.G., Breed, W.P.M., & Nortier, J.W.R. (2012). Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia. Supportive Care in Cancer, 20(12), 3255\u20133260. https:\/\/doi.org\/10.1007\/s00520-012-1465-0","DOI":"10.1007\/s00520-012-1465-0"},{"key":"59","doi-asserted-by":"crossref","unstructured":"van den Hurk, C.J.G., van den Akker-van Marle, M.E., Breed, W.P.M., van de Poll-Franse, L.V., Nortier, J.W.R., & Coebergh, J.W.W. (2013). Impact of scalp cooling on chemotherapy-induced alopecia, wig use and hair growth of patients with cancer. European Journal of Oncology Nursing, 17(5), 536\u2013540. https:\/\/doi.org\/10.1016\/j.ejon.2013.02.004","DOI":"10.1016\/j.ejon.2013.02.004"},{"key":"60","doi-asserted-by":"crossref","unstructured":"Wardley, A.M., Pivot, X., Morales-Vasquez, F., Zetina, L.M., de F\u00e1tima Dias Gaui, M., Reyes, D.O., . . . Torres, A.A. (2010). Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. Journal of Clinical Oncology, 28(6), 976\u2013983. https:\/\/doi.org\/10.1200\/JCO.2008.21.6531","DOI":"10.1200\/JCO.2008.21.6531"},{"key":"61","unstructured":"Yamada, M., Iihara, H., Fujii, H., Ishihara, M., Matsuhashi, N., Takahashi, T., . . . Itoh, Y. (2015). Prophylactic effect of oral minocycline in combination with topical steroid and skin care against panitumumab-induced acneiform rash in metastatic colorectal cancer patients. Anticancer Research, 35(11), 6175\u20136181. http:\/\/ar.iiarjournals.org\/content\/35\/11\/6175.full"},{"key":"62","doi-asserted-by":"crossref","unstructured":"Yap, Y.S., Kwok, L.L., Syn, N., Chay, W.Y., Chia, J.W.K., Tham, C.K., . . . Soong, R.C.T. (2017). Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: A randomized clinical trial. JAMA Oncology, 3(11), 1538\u20131545. https:\/\/doi.org\/10.1001\/jamaoncol.2017.1269","DOI":"10.1001\/jamaoncol.2017.1269"},{"key":"63","doi-asserted-by":"crossref","unstructured":"Yoshimoto, N., Yamashita, T., Fujita, T., Hayashi, H., Tsunoda, N., Kimura, M., . . . Iwata, H. (2010). Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. Breast Cancer, 17(4), 298\u2013302. https:\/\/doi.org\/10.1007\/s12282-009-0171-3","DOI":"10.1007\/s12282-009-0171-3"}],"container-title":["Oncology Nursing Forum"],"original-title":[],"link":[{"URL":"http:\/\/onf.ons.org\/onf\/47\/5\/ons-guidelines-cancer-treatment-related-skin-toxicity","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:50:08Z","timestamp":1763754608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/onf\/47\/5\/ons-guidelinestm-cancer-treatment-related-skin-toxicity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1188\/20.onf.539-556","relation":{},"ISSN":["0190-535X","1538-0688"],"issn-type":[{"value":"0190-535X","type":"print"},{"value":"1538-0688","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,1]]}}}